Neoventures Biotechnology Europe

At Neoventures Biotechnology Europe, we are passionate about pushing the boundaries of innovation in the Biotech and Medtech sector.

Our proteomics platform, named APTAMARKER, is highly innovative in that we do not pre-train probes on recombinant proteins; we apply 268 million aptamer probes to every sample, enabling a holistic approach to proteoform characterization. It is designed to enable agnostic detection of proteoforms directly from plasma, serum, biofluids, or single cells. It accelerates the discovery, validation, and clinical translation of biomarkers, offering a scalable, accessible solution that complements other existing multi-omics tools.

The APTAMARKER platform is designed for academics and biopharma companies pursuing precision medicine. Our added value lies in our ability to overcome the technological barriers of classical proteomics by combining analytical depth with ease of use to reach the required proteoform resolution for clinical applications.

The proteoform-specific probes identified enable the direct creation of custom assays for disease monitoring, patient stratification, and the identification of functional signatures in samples. This novel technology represents a paradigm shift that strengthens the preclinical-to-clinical biomarker workflow by providing broader proteomic coverage than conventional immunoassays, with data ideally formatted for any AI analysis.

Whether for patient stratification, identification of diagnostic biomarkers or functional signatures, or biosensor design for translational research, the Aptamarker platform is a key technology for accelerating R&D while reducing costs and timelines. A universal research solution accelerating clinical translation, suitable for all proteins, all pecies, all biofluids and all diseases.